$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs

$ohcs Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000121390024053154 Filed on June 17, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$639.3K	$450.0K	$1.498M
YoY Change	98.29%	106.48%	22.88%
Cost Of Revenue	$58.06K	$65.49K	$284.4K
YoY Change	-1.85%	7.68%	8.27%
Gross Profit	$581.2K	$384.5K	$1.213M
YoY Change	120.79%	144.73%	26.89%
Gross Profit Margin	90.92%	85.45%	81.01%
Selling, General & Admin	$1.831M	$2.503M	$9.785M
YoY Change	-31.96%	-1777.23%	8.46%
% of Gross Profit	314.96%	651.01%	806.46%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$3.503K	$7.240K	$17.24K
YoY Change	0.03%	-95.14%	-95.07%
% of Gross Profit	0.6%	1.88%	1.42%
Operating Expenses	$1.831M	$2.504M	$9.786M
YoY Change	-31.96%	-1777.39%	8.47%
Operating Profit	-$1.249M	-$2.119M	-$8.573M
YoY Change	-48.52%	-791.64%	6.28%
Interest Expense	-$200.7K	-$246.7K	$614.0K
YoY Change	-274.8%	95.31%	89.29%
% of Operating Profit
Other Income/Expense, Net	-$200.7K	-$291.3K	-$2.529M
YoY Change	-53.46%	0.0%	27.4%
Pretax Income	-$1.450M	-$3.511M	-$11.10M
YoY Change	-49.27%	1717.23%	10.45%
Income Tax	$993.00	$10.00	$2.033K
% Of Pretax Income
Net Earnings	-$1.451M	-$3.510M	-$11.10M
YoY Change	-49.27%	1649.52%	3.53%
Net Earnings / Revenue	-226.98%	-779.96%	-741.33%
Basic Earnings Per Share	-$0.03
Diluted Earnings Per Share	-$0.03	-$0.09	-$0.28
COMMON SHARES
Basic Shares Outstanding	45.79M shares	39.97M shares	39.97M shares
Diluted Shares Outstanding	45.68M shares		39.97M shares

Balance Sheet

Concept	2024 Q2	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$31.97K	$133.9K
YoY Change	-89.99%	-86.61%
Cash & Equivalents	$12.76K	$100.3K
Short-Term Investments	$19.21K	$33.59K
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$602.4K	$572.7K
Other Receivables	$0.00	$100.0K
Total Short-Term Assets	$634.3K	$806.6K
YoY Change	-32.95%	-53.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$32.23K	$39.16K
YoY Change	-53.35%	-30.31%
Goodwill
YoY Change
Intangibles		$0.00
YoY Change		-100.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$228.7K	$263.5K
YoY Change	-80.82%	-78.3%
TOTAL ASSETS
Total Short-Term Assets	$634.3K	$806.6K
Total Long-Term Assets	$228.7K	$263.5K
Total Assets	$863.1K	$1.070M
YoY Change	-59.64%	-63.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.341M	$1.154M
YoY Change	20.45%	56.33%
Accrued Expenses	$1.429M	$1.043M
YoY Change	162.19%	79.32%
Deferred Revenue
YoY Change
Short-Term Debt	$2.136M	$1.856M
YoY Change	96.36%	1223.07%
Long-Term Debt Due	$4.405M	$3.921M
YoY Change	31.94%	73881.89%
Total Short-Term Liabilities	$9.373M	$8.034M
YoY Change	52.29%	424.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$1.590K
YoY Change	-100.0%	-99.94%
Other Long-Term Liabilities	$0.00	$1.592K
YoY Change	-100.0%	-99.44%
Total Long-Term Liabilities	$0.00	$1.592K
YoY Change	-100.0%	-99.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.373M	$8.034M
Total Long-Term Liabilities	$0.00	$1.592K
Total Liabilities	$9.519M	$8.211M
YoY Change	48.58%	79.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$32.01M	-$30.13M
YoY Change	28.82%	58.33%
Common Stock	$45.80K	$39.97K
YoY Change	14.58%	4.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$8.652M	-$7.138M
YoY Change
Total Liabilities & Shareholders Equity	$863.1K	$1.070M
YoY Change	-59.64%	-63.6%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.451M	-$3.510M	-$11.10M
YoY Change	-49.27%	1649.52%	3.53%
Depreciation, Depletion And Amortization	$3.503K	$7.240K	$17.24K
YoY Change	0.03%	-95.14%	-95.07%
Cash From Operating Activities	-$238.7K	-$516.7K	-$3.687M
YoY Change	-77.01%	-48.58%	-8.69%
INVESTING ACTIVITIES
Capital Expenditures		-$4.570K	$35.43K
YoY Change		-116.23%	-38.43%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$2.710K	$222.7K
YoY Change	-100.0%	-102.71%	-68.59%
Cash From Investing Activities	$0.00	-$2.720K	$187.3K
YoY Change	-100.0%	-97.88%	-71.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$1.138M
YoY Change			-158.19%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	179.9K	418.7K	$2.849M
YoY Change	-77.81%	-65.2%	-26.51%
NET CHANGE
Cash From Operating Activities	-238.7K	-516.7K	-$3.687M
Cash From Investing Activities	0.000	-2.720K	$187.3K
Cash From Financing Activities	179.9K	418.7K	$2.849M
Net Change In Cash	-58.81K	-100.7K	-$650.7K
YoY Change	139.55%	-243.56%	-232.75%
FREE CASH FLOW
Cash From Operating Activities	-$238.7K	-$516.7K	-$3.687M
Capital Expenditures		-$4.570K	$35.43K
Free Cash Flow		-$512.1K	-$3.722M
YoY Change		-50.42%	-9.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38785879	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39967538	shares
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	333-261849
CY2023	dei	Entity Registrant Name EntityRegistrantName	OPTIMUS HEALTHCARE SERVICES, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	65-0181535
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1400 Old Country Road
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 306
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Westbury
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11590
CY2023	dei	City Area Code CityAreaCode	(516)
CY2023	dei	Local Phone Number LocalPhoneNumber	806-4201
CY2023	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
CY2023	dei	Security12b Title Security12bTitle	None
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	11731000	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45794664	shares
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	759
CY2023	dei	Auditor Name AuditorName	Seligson & Giannattasio, LLP
CY2023	dei	Auditor Location AuditorLocation	White Plains, New York
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100319	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	751017	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	572707	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	525064	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	100000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	200689	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33592	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	104877	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	144199	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	806618	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1725846	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	224316	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	339614	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39164	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56196	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2750	usd
CY2022Q4	us-gaap	Goodwill Goodwill	815500	usd
CY2023Q4	us-gaap	Assets Assets	1070098	usd
CY2022Q4	us-gaap	Assets Assets	2939906	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1154309	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	738395	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1043270	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	581802	usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	135744	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	140060	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3915732	usd
CY2023Q4	ohcs	Paycheck Protection Program Loan Current PaycheckProtectionProgramLoanCurrent	5304	usd
CY2022Q4	ohcs	Paycheck Protection Program Loan Current PaycheckProtectionProgramLoanCurrent	5304	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	59765	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	67052	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8034124	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1532813	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	175344	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283092	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	2759961	usd
CY2023Q4	us-gaap	Program Rights Obligations Noncurrent ProgramRightsObligationsNoncurrent	1592	usd
CY2022Q4	us-gaap	Program Rights Obligations Noncurrent ProgramRightsObligationsNoncurrent	6562	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8211060	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4582428	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39967598	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39967598	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38286598	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38286598	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	39968	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	38287	usd
CY2023Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	550	usd
CY2022Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	1206	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22947709	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17343671	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-30133916	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19032561	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7137581	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1641289	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-3381	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-1233	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-7140962	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1642522	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1070098	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2939906	usd
CY2023	us-gaap	Revenues Revenues	1497779	usd
CY2022	us-gaap	Revenues Revenues	1218882	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	284420	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	262689	usd
CY2023	us-gaap	Gross Profit GrossProfit	1213359	usd
CY2022	us-gaap	Gross Profit GrossProfit	956193	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4466890	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3315895	usd
CY2023	us-gaap	Other General Expense OtherGeneralExpense	2707585	usd
CY2022	us-gaap	Other General Expense OtherGeneralExpense	2699958	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2161411	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2330568	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	450378	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	675943	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9786264	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	9022364	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-8572905	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-8066171	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1155772	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1131629	usd
CY2023	us-gaap	Interest Expense InterestExpense	614024	usd
CY2022	us-gaap	Interest Expense InterestExpense	324385	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-218238	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-37979	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-127927	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	815500	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	78510	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-183241	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	16200	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	700	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2528565	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1984720	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11101470	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10050891	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2033	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	674292	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11103503	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10725183	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2148	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	308	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-11101355	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-10724875	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11103503	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10725183	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.28
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.28
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39967538	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38785879	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5412484	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1956000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	467500	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	111847	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	561100	usd
CY2022	ohcs	Stock Issued During Period Value Stock Repurchased In Connection With Painscript Diversture StockIssuedDuringPeriodValueStockRepurchasedInConnectionWithPainscriptDiversture	-3600000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	857835	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3315895	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10725183	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1642522	usd
CY2023	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	136827	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1275000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	15281	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4451609	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11103503	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-7140962	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11103503	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10725183	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17235	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	349851	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4466890	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3315895	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	78510	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-183241	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-218238	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-37979	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-127927	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	815500	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1155772	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1131629	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	263	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4055	usd
CY2022	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	666616	usd
CY2023	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	-53046	usd
CY2022	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	53256	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-71285	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	31331	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	415912	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	631537	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	461468	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	143439	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3686663	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4037342	usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	9000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	936330	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2203666	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	713621	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1503666	usd
CY2023	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	35431	usd
CY2022	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	57540	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	187278	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	651460	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1275000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1956000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	136827	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1935000	usd
CY2023	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	1719800	usd
CY2023	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan	4970	usd
CY2022	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan	4920	usd
CY2023	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	4316	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	10019	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2848687	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3876061	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-650698	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	490179	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	751017	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	260838	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100319	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	751017	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	299700	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	258000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	2033	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	467500	usd
CY2022	ohcs	Warrants Issued With Convertible Notes Payable WarrantsIssuedWithConvertibleNotesPayable	857835	usd
CY2022	ohcs	Common Stock Issued To Satisfy Debt And Accounts Payables CommonStockIssuedToSatisfyDebtAndAccountsPayables	561100	usd
CY2022	ohcs	Common Stock Issued With Convertible Notes Payable CommonStockIssuedWithConvertibleNotesPayable	111847	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. Nature of operations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Optimus Healthcare Services, Inc. (formerly Between Dandelions, Inc., “Optimus”, “Company”) was initially organized under the laws of Florida on February 26, 1990, as Phoenix Management Associates, Inc. Over the ensuing years, the Company made a series of amendments to its Articles of Incorporation relating to authorization of various series of Preferred Shares and made a series of name changes. The current name of Optimus Healthcare Services, Inc. became effective with the State of Florida on January 24, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company is dedicated to advancing access to clinical trial research through its portfolio company Clinical Research Alliance, Inc. (“CRA”), and until December 2023 when it discontinued operations of its early stage pharmacy operation, through its portfolio company Worker’s Health Rx (d/b/a “Vitality Rx”).</span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of equity issued for services, valuation of equity associated with convertible debt, the valuation of derivative liabilities, and the valuation of deferred tax assets. Actual results could differ from these estimates.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in certificates of deposit, deposit accounts or treasury bills. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.</p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100319	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	751017	usd
CY2022	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	363153	usd
CY2023	ohcs	Annual Revenue Percentage AnnualRevenuePercentage	0.374	pure
CY2022	ohcs	Annual Revenue Percentage AnnualRevenuePercentage	0.571	pure
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283092	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	250	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2750	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	345903	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	815500	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4466890	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3315895	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	11288	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.50	pure
CY2023	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	3000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9692914	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7624164	shares
CY2023	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company entered into a lease agreement commencing on July 1, 2023 through June 30, 2026 for 2,153 square feet of office space located at One Dupont Street, Suite 112, Plainview, New York, 11803.
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	158	usd
CY2023	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.075	pure
CY2023	us-gaap	Other Expenses OtherExpenses	133710	usd
CY2022	us-gaap	Other Expenses OtherExpenses	120528	usd
CY2023Q4	ohcs	Rightofuseasset Office Lease RightofuseassetOfficeLease	371832	usd
CY2022Q4	ohcs	Rightofuseasset Office Lease RightofuseassetOfficeLease	456819	usd
CY2023Q4	ohcs	Rights Of Use Assets Equipment Lease RightsOfUseAssetsEquipmentLease	5676	usd
CY2022Q4	ohcs	Rights Of Use Assets Equipment Lease RightsOfUseAssetsEquipmentLease	2063	usd
CY2023Q4	ohcs	Accumulated Amortization Accumulated Amortization AccumulatedAmortizationAccumulatedAmortization	153192	usd
CY2022Q4	ohcs	Accumulated Amortization Accumulated Amortization AccumulatedAmortizationAccumulatedAmortization	119268	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	224316	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	339614	usd
CY2023Q4	ohcs	Operating Lease Liability Office Lease OperatingLeaseLiabilityOfficeLease	229433	usd
CY2022Q4	ohcs	Operating Lease Liability Office Lease OperatingLeaseLiabilityOfficeLease	348081	usd
CY2023Q4	ohcs	Operating Lease Liability Equipment Lease OperatingLeaseLiabilityEquipmentLease	5676	usd
CY2022Q4	ohcs	Operating Lease Liability Equipment Lease OperatingLeaseLiabilityEquipmentLease	2063	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	59765	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	67052	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	175344	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	69477	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	71323	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	73223	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	49677	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	263700	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	28591	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	235109	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100319	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	751017	usd
CY2023Q4	ohcs	Working Capital Deficit WorkingCapitalDeficit	7227506	usd
CY2022Q4	ohcs	Working Capital Deficit WorkingCapitalDeficit	193033	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11103503	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10725183	usd
CY2020Q4	us-gaap	Preferred Stock Conversion Basis PreferredStockConversionBasis	The Series A Preferred Stock votes and is convertible at a rate of 1 preferred share to 1.25 common shares.
CY2023Q4	ohcs	Business Acquisition Percentage Of Voting Interest Acquired BusinessAcquisitionPercentageOfVotingInterestAcquired	0.73	pure
CY2020Q4	ohcs	Business Acquisition Percentage Of Voting Interest Acquired BusinessAcquisitionPercentageOfVotingInterestAcquired	0.51	pure
CY2021Q4	us-gaap	Memberships In Exchanges Owned MembershipsInExchangesOwned	425000	usd
CY2021Q4	us-gaap	Shares Issued SharesIssued	425000	shares
CY2023	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	1750	usd
CY2023	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	218238	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5297500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.74
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y5M4D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3365000	shares
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	815500	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-37979	usd
CY2022Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	2000000	shares
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	400000	shares
CY2022Q4	us-gaap	Loans Payable LoansPayable	200000	usd
CY2022Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	100000	usd
CY2022Q4	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	3600000	usd
CY2022Q4	us-gaap	Beneficial Interest BeneficialInterest	100000	usd
CY2022Q4	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	3500000	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	3627927	usd
CY2022Q4	us-gaap	Gain Loss On Sale Of Property GainLossOnSaleOfProperty	127927	usd
CY2023	ohcs	Coupon Percentage CouponPercentage	0.12	pure
CY2022Q3	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	362000	shares
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	100000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	200689	usd
CY2023Q4	ohcs	Aggregate Principal Amount AggregatePrincipalAmount	200000	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	100689	usd
CY2023Q4	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.20	pure
CY2023Q4	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	100000	usd
CY2023	us-gaap	Liabilities Average Amount Outstanding LiabilitiesAverageAmountOutstanding	100000	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	19880	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	56696	usd
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	43784	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	23896	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	63664	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	80592	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24500	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24396	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39164	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56196	usd
CY2023	us-gaap	Depreciation Depreciation	16235	usd
CY2022	us-gaap	Depreciation Depreciation	3948	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	327440	usd
CY2022Q4	ohcs	Gross Unrealized Loss GrossUnrealizedLoss	183241	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	144199	usd
CY2023	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	78510	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-183241	usd
CY2023	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	161269	usd
CY2023	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	82759	usd
CY2022	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	203371	usd
CY2022	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	20130	usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	135744	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	140060	usd
CY2023	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.0164	pure
CY2023	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	4316	usd
CY2022	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	10019	usd
CY2020Q2	us-gaap	Loans Receivable With Fixed Rates Of Interest1 LoansReceivableWithFixedRatesOfInterest1	145683	usd
CY2020Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	126546	usd
CY2023	us-gaap	Loans Receivable Description Of Variable Rate Basis LoansReceivableDescriptionOfVariableRateBasis	The unforgiven portion of the PPP loan totaling $19,137 is payable over five years at an interest rate of 1%, with a deferral of payments for the first twelve months.
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1592	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5304	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	3915732	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2759961	usd
CY2021Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2000000	shares
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5000000	shares
CY2023	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4641000	shares
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	1275000	usd
CY2023	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	1.25
CY2023	ohcs	Preferred Stock Voting Rightsshare PreferredStockVotingRightsshare	1.25
CY2020Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	9998899	shares
CY2020Q4	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	9998889	shares
CY2023Q2	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	250000	shares
CY2023Q4	us-gaap	Share Price SharePrice	1.24
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.24
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.4471	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0425	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.72
CY2022	ohcs	Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Term Options Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingTermOptionsGranted	P10Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2767500	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.8
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5895000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.69
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6440000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.24
CY2023	ohcs	Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Term Options Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingTermOptionsGranted	P10Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2452500	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.58
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9882500	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.43
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M28D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3181250	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.24
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y4M2D
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4466890	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3315895	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5358833	usd
CY2023	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited	891943	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	6218627	usd
CY2023	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.25	pure
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2033	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7626	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2033	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7626	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	666616	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	666616	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2033	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	674292	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.0406	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.0646	pure
CY2023	ohcs	Effective Income Tax Rate Reconciliation Convertible Debt EffectiveIncomeTaxRateReconciliationConvertibleDebt	-0.0312	pure
CY2022	ohcs	Effective Income Tax Rate Reconciliation Convertible Debt EffectiveIncomeTaxRateReconciliationConvertibleDebt	-0.0302	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0001	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0002	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.122	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.151	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.0161	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0006	pure
CY2022	ohcs	Effective Income Tax Rate Reconciliation Painscript Transaction EffectiveIncomeTaxRateReconciliationPainscriptTransaction	0.0128	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0432	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0002	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.067	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	1571322	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	1393319	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	360931	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	198703	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	61446	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	91510	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	1766	usd
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	53151	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	311419	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	54941	usd
CY2023Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	8264	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	6826	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	673988	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	59113	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2989136	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1857563	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	9700	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	7172	usd
CY2023Q4	ohcs	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	58625	usd
CY2022Q4	ohcs	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	88758	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	48925	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	81586	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	2940211	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1775977	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2940211	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1775977	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	7482484	usd
CY2003	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1164000	usd
CY2023Q4	us-gaap	Bridge Loan BridgeLoan	350000	usd
CY2023	ohcs	Percentage Of Unconverted Outstanding Principal PercentageOfUnconvertedOutstandingPrincipal	0.12	pure
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.0625
CY2023	ohcs	Percentage Of Closing Sale Price PercentageOfClosingSalePrice	1	pure
CY2023Q4	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	0.0625
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2023	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	20000	usd
CY2023	dei	Security Exchange Name SecurityExchangeName	NONE
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2023Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.28
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.28
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit		usd
CY2023	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	ohcs	Warrants Issued With Convertible Notes Payable WarrantsIssuedWithConvertibleNotesPayable		usd
CY2023	ohcs	Common Stock Issued To Satisfy Debt And Accounts Payables CommonStockIssuedToSatisfyDebtAndAccountsPayables		usd
CY2023	ohcs	Common Stock Issued With Convertible Notes Payable CommonStockIssuedWithConvertibleNotesPayable		usd
CY2023	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales		usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis		usd
CY2023Q4	ohcs	Gross Unrealized Gain GrossUnrealizedGain		usd
CY2022Q4	ohcs	Gross Unrealized Gain GrossUnrealizedGain		usd
CY2023Q4	ohcs	Gross Unrealized Loss GrossUnrealizedLoss		usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses		pure
CY2023	ohcs	Effective Income Tax Rate Reconciliation Painscript Transaction EffectiveIncomeTaxRateReconciliationPainscriptTransaction		pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent		pure
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts		usd
CY2023Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001892025

Files In Submission

Name	View Source	Status
0001213900-24-053154-index-headers.html	Edgar Link	pending
0001213900-24-053154-index.html	Edgar Link	pending
0001213900-24-053154.txt	Edgar Link	pending
0001213900-24-053154-xbrl.zip	Edgar Link	pending
ea0207615-10k_optimus.htm	Edgar Link	pending
ea020761501ex10-15_optimus.htm	Edgar Link	pending
ea020761501ex21-1_optimus.htm	Edgar Link	pending
ea020761501ex31-1_optimus.htm	Edgar Link	pending
ea020761501ex31-2_optimus.htm	Edgar Link	pending
ea020761501ex32-1_optimus.htm	Edgar Link	pending
ea020761501ex32-2_optimus.htm	Edgar Link	pending
ea020761501ex4-6_optimus.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ohcs-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ohcs-20231231_cal.xml	Edgar Link	unprocessable
ohcs-20231231_def.xml	Edgar Link	unprocessable
ohcs-20231231_pre.xml	Edgar Link	unprocessable
ohcs-20231231_lab.xml	Edgar Link	unprocessable
ea0207615-10k_optimus_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs

2024 Q2 Form 10-K Financial Statement

#000121390024053154 Filed on June 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OHCS Optimus Healthcare Services, Inc. Stock $ohcs

2024 Q2 Form 10-K Financial Statement

#000121390024053154 Filed on June 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs